{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:34:58Z","timestamp":1789832098723,"version":"4.0.1"},"reference-count":40,"publisher":"Bentham Science Publishers Ltd.","issue":"3","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To investigate injection site pain (ISP) and other injection site outcomes caused by biologics administered alongside citrate-free (CF) and citrate-containing (CC) formula-tions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Electronic literature databases (Medline, Embase, and Cochrane Library) were systemati-cally searched for clinical trials and observational studies reporting on injection site outcomes after subcutaneous administration of biologics. Studies with unknown excipient formulations were ex-cluded. The primary outcome was ISP, and secondary outcomes included any other reported injec-tion site reactions (ISRs). Meta-analysis approaches were used to aggregate evidence identified via the conducted systematic literature review.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of two observational studies, two cross-over\/sequential trials, and three head-to-head comparison trials directly comparing CF with CC biologics were identified, as well as seven placebo-controlled trials. Evidence from five of the seven direct comparison studies suggested re-duced pain perception at the injection site when CF formulations were applied. Findings for other ISRs were balanced between both formulations, with slightly favorable results for preparations without citrate. A meta-analysis of placebo-controlled trials found no significant difference between arms with CF formulations and placebo regarding the proportion of patients experiencing ISP (OR 0.62, 95% CI 0.30-1.28).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Excipient formulations are rarely specified in studies assessing pain and other ISRs of subcutaneously administered biologics. The available data indicate that subcutaneous administration of biologic agents without citrate may be associated with lower pain perception outcomes compared with treatment using CC formulations. Importantly, ISP is influenced by many factors which may have affected the results. More research is needed to assess how formulation excipients influence ISRs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573397118666220829123713","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T07:38:57Z","timestamp":1661845137000},"page":"303-313","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Systematic Literature Review of Injection Site Pain Perception in Adult\nPatients Treated with Citrate-Free and Citrate-Containing Biologic Agents"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1434-9380","authenticated-orcid":true,"given":"Sophia","family":"Junker","sequence":"additional","affiliation":[{"name":"Ingress-Health HWM GmbH, a wholly owned subsidiary of Cytel Inc., Potsdamer Str. 58, 10785 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ebert","sequence":"additional","affiliation":[{"name":"Amgen GmbH, Riesstra\u00dfe 24, 80992 M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bartsch","sequence":"additional","affiliation":[{"name":"Amgen GmbH, Riesstra\u00dfe 24, 80992 M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-3-319-66884-0_12","author":"Nathan J.J.","year":"2018","unstructured":"Nathan J.J.; Ramchandani M.; Kaur P.; Manufacturing of Biologics. Biologic and Systemic Agents in Dermatology 2018,101-110","journal-title":"Biologic and Systemic Agents in Dermatology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","volume":"83","author":"Kuek A.","year":"2007","unstructured":"Kuek A.; Hazleman B.L.; Ost\u00f6r A.J.K.; Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution. Postgrad Med J 2007,83(978),251-260","journal-title":"Postgrad Med J"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"9675","DOI":"10.3748\/wjg.v20.i29.9675","volume":"20","author":"Renna S.","year":"2014","unstructured":"Renna S.; Cottone M.; Orlando A.; Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014,20(29),9675-9690","journal-title":"World J Gastroenterol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","volume":"18","author":"R\u00f8nholt K.","year":"2017","unstructured":"R\u00f8nholt K.; Iversen L.; Old and new biological therapies for psoriasis. Int J Mol Sci 2017,18(11),2297","journal-title":"Int J Mol Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"Singh J.A.","year":"2016","unstructured":"Singh J.A.; Saag K.G.; Bridges S.L.; 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016,68,1-26","journal-title":"Arthritis Rheumatol"},{"key":"ref=6","unstructured":"World Health Organization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs), Annex 2, TRS No 1004. Technical Report, 2016."},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"Cohen S.","year":"2017","unstructured":"Cohen S.; Genovese M.C.; Choy E.; Perez-Ruiz F.; Matsumoto A.; Pavelka K.; Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017,76(10),1679-1687","journal-title":"Ann Rheum Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/14712598.2018.1421169","volume":"18","author":"Lamanna W.C.","year":"2018","unstructured":"Lamanna W.C.; Holzmann J.; Cohen H.P.; Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opin Biol Ther 2018,18(4),369-379","journal-title":"Expert Opin Biol Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/9780470571224.pse521","author":"Irvine D.J.","year":"2013","unstructured":"Irvine D.J.; Su X.; Kwong B.; Routes of Delivery for Biological Drug Products. In: Pharmaceutical Sciences Encyclopedia 2013,1-48","journal-title":"In: Pharmaceutical Sciences Encyclopedia"},{"key":"ref=10","first-page":"2563","volume":"30","author":"Furst D.E.","year":"2003","unstructured":"Furst D.E.; Schiff M.H.; Fleischmann R.M.; Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003,30(12),2563-2571","journal-title":"J Rheumatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13555-019-00341-2","volume":"10","author":"Grace E.","year":"2020","unstructured":"Grace E.; Goldblum O.; Renda L.; Injection site reactions in the Federal Adverse Event Reporting System (FAERS) post-marketing database vary among biologics approved to treat moderate-to-severe psoriasis. Dermatol Ther 2020,10(1),99-106","journal-title":"Dermatol Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone E.C.","year":"2004","unstructured":"Keystone E.C.; Kavanaugh A.F.; Sharp J.T.; Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004,50(5),1400-1411","journal-title":"Arthritis Rheum"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/tcrm.2007.3.1.133","volume":"3","author":"Mease P.J.","year":"2007","unstructured":"Mease P.J.; Adalimumab in the treatment of arthritis. Ther Clin Risk Manag 2007,3(1),133-148","journal-title":"Ther Clin Risk Manag"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"van de Putte L.B.A.","year":"2004","unstructured":"van de Putte L.B.A.; Atkins C.; Malaise M.; Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004,63(5),508-516","journal-title":"Ann Rheum Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"Weinblatt M.E.","year":"2003","unstructured":"Weinblatt M.E.; Keystone E.C.; Furst D.E.; Moreland L.W.; Weisman M.H.; Birbara C.A.; Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003,48(1),35-45","journal-title":"Arthritis Rheum"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/dom.12304","volume":"16","author":"Heise T.","year":"2014","unstructured":"Heise T.; Nosek L.; Dellweg S.; Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: A single-centre, randomized controlled trial. Diabetes Obes Metab 2014,16(10),971-976","journal-title":"Diabetes Obes Metab"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2377-8-38","volume":"8","author":"Jaber A.","year":"2008","unstructured":"Jaber A.; Bozzato G.B.; Vedrine L.; Prais W.A.; Berube J.; Laurent P.E.; A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol 2008,8(1),38","journal-title":"BMC Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1742-7843.2006.pto_271.x","volume":"98","author":"Laursen T.","year":"2006","unstructured":"Laursen T.; Hansen B.; Fisker S.; Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol 2006,98(2),218-221","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"S582","DOI":"10.1093\/ecco-jcc\/jjx180.1046","volume":"12","author":"Gely C.","year":"2018","unstructured":"Gely C.; Mar\u00edn L.; Gordillo J.; N032 Impact of pain due to subcutaneous administration of a biological drug. J Crohn\u2019s Colitis 2018,12(Suppl. 1),S582-S583","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","volume":"340","author":"Moher D.","year":"2010","unstructured":"Moher D.; Hopewell S.; Schulz K.F.; CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ 2010,340,c869","journal-title":"BMJ"},{"key":"ref=21","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal: User guide for company evidence submission template. 2015. Available from:"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(10)70065-7","volume":"10","author":"Tacconelli E.","year":"2010","unstructured":"Tacconelli E.; Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. Lancet Infect Dis 2010,10,226","journal-title":"Lancet Infect Dis"},{"key":"ref=23","first-page":"A233.2-4","volume":"26","author":"Mart\u00ednez-Casanova J","year":"2019","unstructured":"Mart\u00ednez-Casanova J; Acin P; Carballo N; Gonzalez R; Navarrete Rouco E; Perez Garc\u00eda C.; 5PSQ-070 Influence of pathology in injection pain reduction with a new formulation of original adalimumab. Patient Safety and Quality Assurance. European J Hospital Pharm 2019,26(Suppl. 1),A233.2-4","journal-title":"European J Hospital Pharm"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14397595.2018.1520426","volume":"29","author":"Yoshida T.","year":"2019","unstructured":"Yoshida T.; Otaki Y.; Katsuyama N.; Seki M.; Kubota J.; New adalimumab formulation associated with less injection site pain and improved motivation for treatment. Mod Rheumatol 2019,29(6),949-953","journal-title":"Mod Rheumatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"A114","DOI":"10.1136\/ejhpharm-2018-eahpconf.246","volume":"25","author":"Mu\u00f1oz N.H.","year":"2018","unstructured":"Mu\u00f1oz N.H.; Rosado A.A.; Muniesa B.H.; L\u00e1zaro C.B.; Rom\u00e1n A.F.; Alonso A.P.; 4CPS-155 Comparative study for evaluation of the pain, ease of use and preference between two adalimumab administration devices: study adap2017. Eur J Hosp Pharm 2018,25(Suppl. 1),A114-A115","journal-title":"Eur J Hosp Pharm"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40744-016-0041-3","volume":"3","author":"Nash P.","year":"2016","unstructured":"Nash P.; Vanhoof J.; Hall S.; Randomized crossover comparison of injection site pain with 40 mg\/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther 2016,3(2),257-270","journal-title":"Rheumatol Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"Griffiths C.E.M.","year":"2015","unstructured":"Griffiths C.E.M.; Reich K.; Lebwohl M.; Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet 2015,386(9993),541-551","journal-title":"Lancet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"S357","DOI":"10.1093\/ecco-jcc\/jjx180.624","volume":"12","author":"Krishnan E.","year":"2018","unstructured":"Krishnan E.; Zhang N.; Wang H.; P497 Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studies. J Crohn\u2019s Colitis 2018,12(Suppl. 1),S357-S57","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/art.37711","volume":"65","author":"Weinblatt M.E.","year":"2013","unstructured":"Weinblatt M.E.; Schiff M.; Valente R.; Head\u2010to\u2010head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013,65(1),28-38","journal-title":"Arthritis Rheum"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","volume":"72","author":"Burmester G.R.","year":"2012","unstructured":"Burmester G.R.; Weinblatt M.E.; Mcinnes I.B.; Porter D.; Barbarash O.; Vatutin M.; Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2012,72(9),1445-1452","journal-title":"Ann Rheum Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","volume":"72","author":"Genovese M.C.","year":"2013","unstructured":"Genovese M.C.; Durez P.; Richards H.B.; Efficacy and safety of secukinumab in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013,72(6),863-869","journal-title":"Ann Rheum Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/RHU.0000000000000276","volume":"21","author":"Genovese M.C.","year":"2015","unstructured":"Genovese M.C.; Silverman G.J.; Emery P.; Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in a heterogeneous rheumatoid arthritis population: Results from a randomized, placebo-controlled, phase 3 trial (FLEX-O). J Clin Rheumatol 2015,21(5),231-238","journal-title":"J Clin Rheumatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"Papp K.A.","year":"2016","unstructured":"Papp K.A.; Reich K.; Paul C.; A prospective phase III, randomized, double\u2010blind, placebo\u2010controlled study of brodalumab in patients with moderate\u2010to\u2010severe plaque psoriasis. Br J Dermatol 2016,175(2),273-286","journal-title":"Br J Dermatol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","volume":"9","author":"Sandborn W.J.","year":"2011","unstructured":"Sandborn W.J.; Schreiber S.; Feagan B.G.; Certolizumab pegol for active Crohn\u2019s disease: A placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011,9(8),670-678.e3","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e000900","DOI":"10.1136\/rmdopen-2019-000900","volume":"5","author":"Smolen J.S.","year":"2019","unstructured":"Smolen J.S.; Goncalves J.; Quinn M.; Benedetti F.; Lee J.Y.; Era of biosimilars in rheumatology: Reshaping the healthcare environment. RMD Open 2019,5(1),e000900","journal-title":"RMD Open"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery P.","year":"2009","unstructured":"Emery P.; Fleischmann R.M.; Moreland L.W.; Golimumab, a human anti-tumor necrosis factor \u03b1 monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009,60(8),2272-2283","journal-title":"Arthritis Rheum"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11095-021-03047-3","volume":"38","author":"Shi G.H.","year":"2021","unstructured":"Shi G.H.; Pisupati K.; Parker J.G.; Subcutaneous injection site pain of formulation matrices. Pharm Res 2021,38(5),779-793","journal-title":"Pharm Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s11095-021-03075-z","volume":"38","author":"Eaton M.","year":"2021","unstructured":"Eaton M.; Que Z.; Zhang J.; Multi-electrode array of sensory neurons as an in vitro platform to identify the nociceptive response to pharmaceutical buffer systems of injectable biologics. Pharm Res 2021,38(7),1179-1186","journal-title":"Pharm Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1523\/JNEUROSCI.2087-20.2021","volume":"41","author":"Yang Y.L.","year":"2021","unstructured":"Yang Y.L.; Lai T.W.; Citric acid in drug formulations causes pain by potentiating acid-sensing ion channel 1. J Neurosci 2021,41(21),4596-4606","journal-title":"J Neurosci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"Usach I.","year":"2019","unstructured":"Usach I.; Martinez R.; Festini T.; Peris J.E.; Subcutaneous injection of drugs: Literature review of factors influencing pain sensation at the injection site. Adv Ther 2019,36(11),2986-2996","journal-title":"Adv Ther"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397118666220829123713","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/208159\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397118666220829123713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T07:16:57Z","timestamp":1691392617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/208159\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397118666220829123713","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}